Metrics as of 10/17/2026, 12:56 AM (Berlin time), refresh in progress.
Genenta Science S.p.A.
Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors. Its activities and acquisition strategy covers aerospace, defense, national security, and biotechnology/biosecurity. Genenta Science…
1D
+0.8%
1W
-14.0%
1M
-8.9%
6M
-7.5%
YTD
-54.7%
1Y
-79.0%
2Y
-88.5%
5Y
–
10Y
–
Next earnings date
03/03/2027 (in 137 days)
Volatility around earnings
~15% stronger price swings than usual
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 02/10/2024
P/E
-1.82
P/B
0.58
EV/EBITDA
-2.23
RETURN ON EQUITY
-12.3%
NET MARGIN
0.0%
DEBT/EQUITY
0.35
DIVIDEND YIELD
0.0%
AS OF
31/12/2025
FREE FLOAT
76.0%
FLOAT SHARES
13,867,981
AVG. DAILY VOLUME (30D)
60,013
Genenta Science S.p.A. is a company in the Industrials sector, Aerospace & Defense industry, headquartered in Italy.
The CEO is Pierluigi Paracchi, the company employs around 9 people.
The IPO was on 15/12/2021; the stock trades on NASDAQ under the ticker GNTA.
1 analysts rate the stock, the consensus is Buy (as of 02/10/2024).
This is an external assessment, not a statement by Market Jury.
The next earnings date is 03/03/2027.
Around past earnings, price swings were roughly 15% stronger than usual.
No, Genenta Science currently does not pay a dividend.
Comparable stocks include GE Aerospace, RTX, Boeing Company, Lockheed Martin, Howmet Aerospace, General Dynamics, Northrop Grumman and TransDigm Group.
Clicking "Analyze stock" lets five strategies assess Genenta Science against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.